Treatment-resistant MDD

Treatment-resistant MDD

• A. Quetiapine, olanzapine, risperidone, ziprasidone
• B. Adjunctive treatment for MDD
• C. Clozapine, olanzapine, quetiapine, risperidone
• D. Antagonism in dopaminergic pathways

Answer: (A)

Augmenting an antidepressant with a second-generation antipsychotic is a well-supported approach for treatment-resistant MDD. The four agents listed—quetiapine, olanzapine, risperidone, and ziprasidone—are all second-generation antipsychotics with evidence for adjunctive use in TRD, helping to boost response and remission when antidepressants alone aren’t enough. They’re chosen because they can enhance mood symptoms and, in some cases, improve sleep and energy, though they require careful monitoring for metabolic side effects and, with ziprasidone, QT interval changes. Clozapine is not used for TRD; it’s reserved for treatment-resistant schizophrenia due to its safety profile. Antagonism in dopaminergic pathways describes a mechanism these drugs share, but the question targets a treatment strategy rather than a mechanistic description, and the other option doesn’t fit that clinical use.

Augmenting an antidepressant with a second-generation antipsychotic is a well-supported approach for treatment-resistant MDD. The four agents listed—quetiapine, olanzapine, risperidone, and ziprasidone—are all second-generation antipsychotics with evidence for adjunctive use in TRD, helping to boost response and remission when antidepressants alone aren’t enough. They’re chosen because they can enhance mood symptoms and, in some cases, improve sleep and energy, though they require careful monitoring for metabolic side effects and, with ziprasidone, QT interval changes. Clozapine is not used for TRD; it’s reserved for treatment-resistant schizophrenia due to its safety profile. Antagonism in dopaminergic pathways describes a mechanism these drugs share, but the question targets a treatment strategy rather than a mechanistic description, and the other option doesn’t fit that clinical use.